Identification of RdRp-NiRAN/JAK1 Dual-Target Drugs for COVID-19 Treatment
The Journal of Physical Chemistry B · 2024
DOI: 10.1021/acs.jpcb.4c06123 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Physical Chemistry B, 2024. Verfasst von Huixuan Zhao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Frontier Chemistry, School of Chemistry and Chemical Engineering, Shandong University, Qingdao 266237, China. Hauptthemen laut MEDLINE: Janus Kinase 1, COVID-19 Drug Treatment, Antiviral Agents, Molecular Docking Simulation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Taishan Scholar Foundation of Shandong Province, Shandong University.
Abstract (Originalsprache)
Inhibition of virus replication and inflammatory response is important for the treatment of severe COVID-19 patients. RNA-dependent RNA polymerase (RdRp) is indispensable for SARS-CoV-2 replication, and Janus kinase (JAK) 1 inhibitors exert immunosuppressive effects. RdRp/JAK1 dual-target drugs are expected to ameliorate the severity of the COVID-19 disease. The N-terminal nidovirus RdRp-associated nucleotidyltransferase (NiRAN) domain of RdRp is a pseudokinase, and it has structural similarities with JAK1. Herein, we evaluated the inhibitory effects of triphosphate forms of 31 nucleoside drugs in the DrugBank database on the NiRAN domain and JAK1 through a combination of theoretical and experimental methods. By analyzing the three properties of 31 nucleoside drugs (total hydrophobic surface area, number of hydrophobic atoms, and molecular weight), these drugs met the application rule of our developed molecular docking with conformer-dependent charges (MDCC). Based on the MDCC method combined with molecular dynamics simulations, Azvudine and Citicoline among these 31 drugs showed stronger predicted binding affinities with the NiRAN domain as well as JAK1 compared to the reference drug Remdesivir. Further experimental verification, including a thermal shift assay and homogeneous time-resolved fluorescence assay, demonstrated that Azvudine was an RdRp-NiRAN/JAK1 dual-target drug. This work provided a previously unexplored mechanism of Azvudine for COVID-19 treatment and proposed a design concept for RdRp-NiRAN/JAK1 dual-target nucleoside drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Frontier Chemistry, School of Chemistry and Chemical Engineering, Shandong University, Qingdao 266237, China.
- School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China.
- Chemical Engineering and Resource Utilization, College of Chemistry, Northeast Forestry University, Harbin 150040, China.
- Normal School, Shenyang University, Shenyang 110044, China.
- School of Life Sciences, Tsinghua University, Beijing 100084, China.
ORCID-Profile: Lei Sun, Xueping Hu, Weiqiao Deng
Förderung
- National Key Research and Development Program of China
- Taishan Scholar Foundation of Shandong Province
- Shandong University
- National Natural Science Foundation of China
- Youth Innovation Team Project for Talent Introduction and Cultivation in Universities of Shandong Province
Zitieren
APA
Zhao, H., Chang, X., Sun, L., Li, E., Zhang, D., Qi, W., Chai, J., Hu, X., & Deng, W. (2024). Identification of RdRp-NiRAN/JAK1 Dual-Target Drugs for COVID-19 Treatment. The Journal of Physical Chemistry B. https://doi.org/10.1021/acs.jpcb.4c06123
Vancouver
Zhao H, Chang X, Sun L, Li E, Zhang D, Qi W, et al. Identification of RdRp-NiRAN/JAK1 Dual-Target Drugs for COVID-19 Treatment. The Journal of Physical Chemistry B. 2024. doi:10.1021/acs.jpcb.4c06123
BibTeX
@article{Zhao2024,
author = {Zhao, Huixuan and Chang, Xiaoyu and Sun, Lei and Li, Ertong and Zhang, Depeng and Qi, Wentao and Chai, Jijie and Hu, Xueping and Deng, Weiqiao},
title = {Identification of RdRp-NiRAN/JAK1 Dual-Target Drugs for COVID-19 Treatment},
journal = {The Journal of Physical Chemistry B},
year = {2024},
doi = {10.1021/acs.jpcb.4c06123}
}
EUVIMED